Kringle Pharma

Basic Information

Stock Code
4884
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Osaka Prefecture
Establishment Year
December 2001
Listing Year
December 2020
Official Website
https://www.kringle-pharma.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, Zakoo, Nexela Pharma, PeptiDream, SanBio, Helios, RenaScience, QualiPs, Takara Bio, Fuzic, Japan Tissue Engineering, Cocol Port

Overview

Kringle Pharma is an Osaka Prefecture-based pharmaceutical company established in 2001, specializing in the development of therapeutics for intractable diseases, with particular strengths in bio drug discovery technology targeting acute spinal cord injury and ALS.

Current Situation

In fiscal 2023, Kringle Pharma is actively investing in research and development expenses to advance clinical development of drugs for intractable diseases. Its flagship acute spinal cord injury treatment candidate and ALS drug development maintain competitive advantages through unique technologies even in an international competitive environment. Headquartered in Osaka Prefecture, the company listed on the Tokyo Stock Exchange in 2020, successfully raising funds and enhancing corporate value. It partners with multiple pharmaceutical-related companies and research institutions, focusing on bio technology innovation. From a sustainability perspective, it promotes environmentally conscious research and development with reduced environmental impact and fulfills social responsibilities, aiming to expand treatment options for intractable diseases in future business growth. Competitors include advanced bio-pharma companies such as SanBio and PeptiDream, where technological differentiation is key to competitive superiority. Moving forward, it plans to accelerate growth toward 2030 through global market entry and clinical trial expansion.

Trivia

Interesting Facts

  • One of Japan's leading bio ventures specialized in intractable diseases.
  • Achieved early promotion from Tokyo Stock Exchange Mothers to Prime Market.
  • Strengthening collaborations with regional healthcare from Osaka base.
  • One of the pioneering companies in domestic clinical trials for ALS therapeutics.
  • Actively introducing cutting-edge technologies in gene therapy field.
  • High researcher ratio within the company, strong research and development capabilities.
  • Planning technology expansion into diverse treatment areas.
  • Advancing preparations for entry into overseas pharmaceutical markets.
  • Protecting intellectual property through multiple patent applications.
  • Developing and operating proprietary drug discovery platform.

Hidden Connections

  • Occasional collaboration with competitor SanBio in talent and technology for research and development.
  • Cooperative relationships with partner companies Fuzic and Zakoo in drug discovery pipelines.
  • Established long-term clinical research collaborations with medical institutions in Osaka.
  • Some shareholders include major domestic pharmaceutical companies.
  • AI utilization technologies in research and development shared with leading domestic ventures.
  • Regular collaborative activities with patient support groups for intractable diseases.
  • Receiving regional technology support as a university spin-off venture.
  • Actively presenting cutting-edge research at industry academic societies and trade shows.

Future Outlook

Growth Drivers

  • Increasing high demand in intractable disease field
  • Rapid progress in gene therapy technologies
  • Acceleration of clinical development domestically and internationally
  • Expansion of AI and digital technology utilization
  • Growth of bio pharmaceutical market
  • Promotion of new technology approvals through regulatory easing
  • Synergy creation with partner companies
  • Expansion of large-scale funding possibilities
  • Overseas market development and global expansion
  • Expansion of special markets for vaccines and therapeutics
  • Investor trust gained through high-quality data
  • Fostering of internal innovation culture

Strategic Goals

  • Obtain multiple approvals for intractable disease therapeutics
  • Achieve annual sales exceeding 20 billion yen
  • Overseas market sales ratio of 30% or more
  • Build sustainable research and development structure
  • Expand leadership in biotechnology field
  • Establish efficient drug discovery system using AI technology
  • Strengthen key patents and continue new technology development
  • Deepen regional medical collaborations and enhance social contributions
  • Establish diverse product pipelines
  • Build global clinical trial network

Business Segments

Pharmaceutical Development Support Services

Overview
Provides pharmaceutical companies with drug development support services utilizing advanced bio technologies.
Competitiveness
Advanced gene technology-based drug discovery support system
Customers
  • Pharmaceutical companies
  • Biotechnology companies
  • Research institutions
  • Universities
  • Contract Development and Manufacturing Organizations (CDMOs)
Products
  • Gene analysis services
  • Clinical trial support
  • Biomarker discovery
  • Drug candidate evaluation
  • Drug discovery platform

Contract Research Organization (CRO) Services

Overview
Offers diverse preclinical and clinical research and development services to support pharmaceutical development.
Competitiveness
Experienced research team and state-of-the-art facilities
Customers
  • Domestic and international pharmaceutical companies
  • Bio ventures
  • University labs
  • Medical institutions
Products
  • Non-clinical trial outsourcing
  • Formulation development support
  • Safety testing
  • Efficacy evaluation

Bio Preparations Production Support

Overview
Provides comprehensive services for bio preparation production technology and quality management to clients.
Competitiveness
High-quality manufacturing through advanced cell culture and analytical technologies
Customers
  • Pharmaceutical OEM companies
  • Bio pharmaceutical manufacturers
  • Health food companies
Products
  • Cell culture technology
  • Gene expression platform
  • Protein purification
  • Quality control support

Medical Diagnostic Kit Development

Overview
Research, development, and provision of high-sensitivity medical diagnostic kits applying gene technology.
Competitiveness
High-precision testing kit development based on gene-related technologies
Customers
  • Hospitals and testing facilities
  • Pharmaceutical companies
  • Research institutes
  • Diagnostic equipment manufacturers
Products
  • Gene testing kits
  • Biomarker detection kits
  • Assays for early disease diagnosis

Research Reagent Sales

Overview
Supplies high-quality gene and protein-related reagents to research institutions domestically and internationally.
Competitiveness
Wide product lineup and stable supply capacity
Customers
  • University researchers
  • Medical institution research departments
  • Pharmaceutical company labs
  • Bio ventures
Products
  • Antibody preparations
  • Gene-related reagents
  • Biomarker reagents
  • Cell culture reagents

Technology Licensing Business

Overview
Business expansion through licensing of proprietary gene technologies and joint research and development.
Competitiveness
Intellectual property strength and development track record in cutting-edge technologies
Customers
  • Domestic pharmaceutical companies
  • Overseas bio companies
  • University spin-offs
  • Research institutions
Products
  • Patent technology licenses
  • Know-how provision contracts
  • Joint development contracts

Bioinformatics Services

Overview
Provides services to streamline drug discovery research using advanced data analysis and AI technologies.
Competitiveness
Analytical capabilities through latest AI technologies and specialized staff
Customers
  • Pharmaceutical companies
  • University labs
  • Bio ventures
  • Public research institutions
Products
  • Gene data analysis
  • Data mining services
  • AI-based drug discovery support

Pharmaceutical Transportation and Storage Support

Overview
Provides quality maintenance and management services for pharmaceutical transportation and storage.
Competitiveness
Dedicated equipment and reliable logistics system
Customers
  • Pharmaceutical manufacturers
  • Medical institutions
  • Logistics companies
Products
  • Cold chain logistics management
  • Quality-preserving transportation services

Medical Device Related Services

Overview
Supports development and sales of medical devices and rehabilitation-related products.
Competitiveness
Accumulated practical know-how in medical settings
Customers
  • Medical device manufacturers
  • Hospitals
  • Rehabilitation facilities
Products
  • Rehabilitation support products
  • Medical consumables

Investigational Drug Manufacturing Services

Overview
Provides manufacturing and supply services for investigational drugs used in clinical trials.
Competitiveness
Thorough quality control and rapid manufacturing
Customers
  • CROs
  • Pharmaceutical companies
  • Research institutions
Products
  • Preclinical investigational drugs
  • Clinical trial formulations

Biosensor Development

Overview
Provides technologies through biosensor development based on gene technology.
Competitiveness
High-sensitivity and rapid detection technology
Customers
  • Research institutions
  • Medical institutions
  • Manufacturers
Products
  • Gene detection sensors
  • Disease biomarker detection devices

Clinical Reagent Development

Overview
Research, development, and market supply of high-quality reagents for clinical testing.
Competitiveness
Product development based on clinical site needs
Customers
  • Pharmaceutical companies
  • Medical testing facilities
Products
  • Diagnostic reagents
  • Testing kits

Competitive Advantage

Strengths

  • Advanced bio drug discovery technology
  • Research expertise specialized in intractable diseases
  • Possession of specialized gene technologies
  • Robust research and development structure
  • Funding capabilities from Tokyo Stock Exchange listing
  • Advantages of Osaka bio cluster location
  • Diverse researcher network
  • Implementation of advanced clinical development
  • Continuous patent acquisition record
  • Strong partnerships with collaborators

Competitive Advantages

  • Early entry into intractable spinal cord injury and ALS markets
  • Proprietary know-how in gene-related technologies
  • Concentrated development system specialized in core areas
  • Robust and high-quality clinical pipeline
  • Diversified business expansion and B2B support services
  • Strengthened collaborations with domestic and international pharmaceutical companies
  • Fast research and development speed and advanced technology
  • High transparency and reliability as a listed company
  • Evidence from accumulated clinical data
  • Market barriers through intellectual property of proprietary technologies

Threats

  • Market share pressure from intensifying competition
  • Risks of delays in clinical development or approvals
  • Potential difficulty keeping pace with technological innovation speed
  • Business environment changes due to regulatory tightening
  • Increasing funding power of competitors
  • Potential patent infringement issues
  • High difficulty in new market development
  • Overseas expansion risks from international situation changes
  • Rising personnel costs from talent acquisition competition
  • Uncertainty in research funding

Innovations

2024: Progress in Phase II Clinical Trial for ALS Therapeutic

Overview
Clinical trials for therapeutics targeting amyotrophic lateral sclerosis initiated at multiple facilities.
Impact
Expansion of possibilities for new treatment methods

2023: Development of Efficacy Enhancement Technology for Acute Spinal Cord Injury Therapeutics

Overview
Achieved technological results improving drug duration of effect and safety.
Impact
Improved treatment efficacy and reduced side effects

2022: Expansion of Gene Editing Technology Introduction

Overview
Initiated research on new treatment methods using CRISPR/Cas9-based gene editing.
Impact
Strengthening of innovative treatment foundations

2021: AI Utilization for Drug Candidate Exploration

Overview
Built drug efficacy prediction and candidate selection processes using AI analysis technology.
Impact
Significant improvement in drug discovery efficiency

2020: System Enhancement of Drug Discovery Platform

Overview
Improved research efficiency through updates to the comprehensive drug discovery support system.
Impact
Shortened research and development periods

Sustainability

  • Introduction of environmentally friendly laboratory equipment
  • Expansion of low-environmental-impact chemical use
  • Active participation in regional medical support activities
  • Promotion of renewable energy utilization
  • Advancement of waste reduction and resource recycling